ClinicalTrials.gg
CompletedNCT04893330PEPSYUpdated Sep 22, 2023

Interest of Peticate Syneo Infant Formula in Children Allergic to Cow's Milk Protein: Real Life Study

An observational study in Milk Hypersensitivity, sponsored by Nutricia Nutrition Clinique. Completed at 1 site in France. Open to participants aged 8 Months and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-22.

Sponsored by Nutricia Nutrition Clinique (part of Danone) · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
78
Ages
8 Months and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 12 studies in Milk Hypersensitivity with a site in France — 1 open to participants now, 1 under way, none of them phase 3. Milk Hypersensitivity · France.

Started
2021
the only one that year
Observational
2 of 12
none open now
Registered
11th of 12
by date
Lead sponsor
1 of 12
Nutricia Nutrition Clinique

Among the 12 studies in Milk Hypersensitivity with a site in France, this one is the only one that started in 2021, is one of 2 observational ones, and was the 11th registered.

Milk Hypersensitivity

147 studies on the registry are indexed under Milk Hypersensitivity; 26 are open to participants now.

Browse Milk Hypersensitivity studies →

Open to participants now

1 of the 12 studies in Milk Hypersensitivity with a site in France is open now. Recruiting first, the newest first:

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 16 Milk Hypersensitivity studies recruiting now, 1 (6%) sets no upper age limit and 15 (94%) stop at 75 or younger; 15 take children under 18; 1 takes healthy volunteers.

This study: 8 Months and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Milk Hypersensitivity with a site in France, or all of them as a file.
02

Study summary

Nutricia wants to launch a real-life study, to see how the presence of prebiotics and probiotics in the boosted protein hydrolyzate can improve symptoms in the first weeks of use, and supplement the efficacy and safety data of the drug. formula, collected during clinical trials, with real life use. The target population will be children with a definite or suspected diagnosis of APLV, who have never taken a hypoallergenic formula, for whom the doctor decides to prescribe the Pepsicate Syneo formula, regardless of the clinical manifestation of the allergy. These children will be included before the age of 8 months and will be seen again 4 weeks after the prescription. The data from this real-life study will also better characterize the profile of infants taking Pepsicate Syneo. Finally, the perception of the formula by the parents will be collected.

Read the detailed description

Nutricia has developed an infant formula intended for children, APLV, from the class of foodstuffs intended for special medical purposes (DADFMS), called Pepticate Syneo. This hypoallergenic formula is based on high hydrolyzate of whey protein. It also contains:

  • IcFOS and scGOS prebiotic fibers. These oligosaccharides are well tolerated and promote the induction of a favorable gut microbiota and an improvement in faecal characteristics [Arslanoglu 2008, Moro 2006].
  • The probiotic strain Bifidobaterium Breve M-16V. B. breve is the most common species of bifidobacteria in human milk [Martin 2009]. The B. breve M16-V strain, isolated from the stool of a healthy infant, is approved in food by health authorities and conforms to the recommendations of the American Academy of Pediatrics [2000]. It helps promote the implantation of beneficial bacteria in the intestinal microbiota of young children [Akiyama 1994, Taniuchi 2005, van der Aa 2010]. Preclinical data suggest that it reduces the allergic immune response [Hougee 2010, Inoue 2009]. In clinical studies, it helps reduce atopic dermatitis in children with APLV [Hattori 2003, Taniuchi 2005]. In addition, the prebiotic / probiotic combination (also called symbiotic) shows a synergistic effect in mice in reducing allergic manifestations [Schouten 2009]. Used in children born by cesarean section, it helps restore intestinal colonization by bifidobacteria, to a level similar to that of infants born vaginally and breastfed [Chua 2017].

In babies with a suspicion of non-IgE-mediated APLV, this symbiotic mixture (IcFOS, scGOS and B. Breve) allowed a modification of the fecal microbiota in 8 weeks, thus approaching the microbiota of breastfed infants of the same age, with an increase in Bifidobacteria and a decrease in Eubacterium rectale / Clostridium coccoides [Fox 2019].

All the available scientific data suggest an excellent tolerance of the Pepticate Syneo formula, and therapeutic efficacy on the manifestations of APLV, whether or not it is mediated by IgE, while ensuring the nutritional needs of children's growth. [Abrahamse-Berkeveld 2016, Giampietro 2001, Vandenplas 1993, Verwimp 1995].

03

Conditions studied

  • Milk Hypersensitivity

Browse trials for

04

Who can participate

Ages eligible
8 Months and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The target population is made up of children under 8 months of age at inclusion, with a diagnosis or strong suspicion of APLV.

The study plans to include 78 patients.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Child aged ≤ 8 months;
  • Child newly diagnosed with an allergy to cow's milk proteins (APLV), or with a strong suspicion of APLV (mediated by IgE or not), justifying (according to the doctor) the prescription of Pepticate® Syneo® (extensive hydrolyzate cow's milk protein)
  • Child already fed with an infant formula (partially or totally), or whose parents have already made the decision to initiate an infant formula, in addition to or as a follow-up to breastfeeding.
  • Authorization of one or more parents or the child's legal representative to collect personal information about the child and the family.

Exclusion criteria

Exclusion Criteria:

  • Child who has already taken an infant formula such as "high protein hydrolyzate" or "amino acid formula";
  • Child with a to taking symbiotics (eg: short bowel syndrome, parenteral nutrition, post-pyloric nutrition, central venous catheter, etc.)
  • Child with severe APLV requiring the prescription of an amino acid formula;
  • Legal guardian of the protected child (under legal protection, or deprived of liberty by judicial or administrative decision);
  • Legal guardian of the child who is not a beneficiary of a social security scheme.
  • Inability of the legal representative to understand the study protocol, or doctor's doubts about the ability of the will to comply with the protocol.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
78 participants (actual)
Patient registry
No

Groups and cohorts

  • patients

    children under 8 months of age at inclusion, with a diagnosis or strong suspicion of APLV

    Dietary Supplement: pepticate syneo

Interventions

  • Dietary supplementpepticate syneo

    follow up of pepticate syneo for one month

06

What researchers measure

Primary outcomes

  1. effect on general condition

    Assessment of the effect of the PEPTICATE SYNEO formula on the evolution of the general condition of a child with a PPLA using a 4-level Likert scale (worse / identical / improved / resolved)

    Time frame: Day 28

Secondary outcomes

  1. Effect on evolution of allergic symptoms

    Evaluation of the effect of the PEPTICATE SYNEO formula on the evolution of allergy symptoms using a 4-level Likert scale (worse / identical / improved / resolved)

    Time frame: Day 28

  2. effect on evolution of allergic symptoms according to Parents

    Assessment of the effect of the PEPTICATE SYNEO formula on the evolution of allergy symptoms according to the parents using a 4-level Likert scale (worse / identical / improved / resolved)

    Time frame: during one month

  3. acceptability

    Descriptive analysis of the acceptability of PEPTICATE SYNEO by parents using a questionnaire

    Time frame: Day 28

  4. Parent's quality of life

    The quality of life of the parents (FAQL-PB score) will be measured by a Student test on paired samples.

    Time frame: Day 28

  5. CLINICAL PROFILE OF CHILDREN

    Description of the clinical profile of the children at inclusion (Age, anthropometric data; growth; Food history, Risk factors for atopy..).

    Time frame: Day 0

  6. Consumption of the formula

    Evaluation of the infant formula consumption of children before inclusion and during follow-up (lasting 28 days).

    Time frame: during one month

07

Study locations

1 site
  • Cabinet Médical
    Charly, 69390, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2021 to primary completion in May 2022, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2021
First posted
May 19, 2021
StartActual
Jun 23, 2021
Primary completionActual
May 30, 2022
CompletionActual
May 30, 2022
Last update
Sep 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04893330
Responsible party
Sponsor
First posted
May 19, 2021
Start date
Jun 23, 2021
Primary completion
May 30, 2022
Completion
May 30, 2022
Last update
Sep 22, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion